Navigation Links
Thrombosis Risk in Travel Lasting Over Four Hours is Higher: WHO

The World Health Organization (WHO) has said that the risk of developing venous thrombo-embolism (VTE) approximately doubles after travel of four hours or more.

In a research study of global hazards of travel, the WHO, however, says that the absolute risk of developing VTE, if seated and immobile for more than four hours remains relatively low at about 1 in 6000.

According to the study, the two most common manifestations of VTE are deep vein thrombosis (DVT) and pulmonary embolism.

Deep vein thrombosis (DVT) is a condition in which a blood clot, or thrombus, develops in a deep vein - usually in the lower leg. Symptoms of DVT are principally pain, tenderness and swelling of the affected part. DVT can be detected through medical testing and can be treated. DVT can be life threatening when associated with thrombo-embolism.

Thrombo-embolism occurs when a blood clot (from a deep vein thrombosis) in a leg vein breaks off and travels through the body to the lung where it becomes lodged and blocks blood flow. This is known as pulmonary embolism, and symptoms include chest pain and breathing difficulties. VTE can be treated, but if it is not, it can lead to death.

The study showed that plane, train, bus or automobile passengers are at the higher risk of VTE when immobile on journeys of more than four hours. This is due to a stagnation of blood in the veins caused by prolonged immobility, which can promote blood clot formation in veins.

One study within the project examining flights in particular found that those taking multiple flights over a short period of time are also at higher risk. This is because the risk of VTE does not go away completely after a flight is over, and risk remains elevated for about four weeks.

The report shows that a number of other factors increase the risk of VTE during travel, including obesity, being very tall or very short (taller than 1.9 meter
'"/>




Page: 1 2

Related medicine news :

1. Stockings Effective In Reducing The Effects Of Deep Vein Thrombosis
2. Travel in Aircraft can cause Thrombosis
3. Increased Risk For Venous Thrombosis In Cancer Patients
4. Computer System To Predict Deep Vein Thrombosis
5. Tomato Extract Found To Reduce The Risk Of Thrombosis
6. Obesity Linked To Deep Vein Thrombosis
7. Deep Vein Thrombosis Risk Increased During Long Travel
8. Infections Increase Risks Of Deep Vein Thrombosis
9. Long Hours At Computer Screen May Also Cause Deep Vein Thrombosis
10. Thrombosis, a Serious Risk in Children with Leukemia
11. Genetic Variations Associated With Risk of Venous Thrombosis Identified

Post Your Comments:
(Date:11/23/2009)...ce"reform"isamoraloutrage ,, WASHINGTON,Nov.2...ovedforwardtobeginthedebateontheirhealthcare"refor...nggrassrootssenioradvocacygroup,iscallingonallofAm...ivecutstoMedicare.RetireSafePresidentThairPhillips...axes,abortion,andimmigration,whilethesimple,uncomp...
(Date:11/23/2009)...,, WHAT: ,, TheBerylInstitute, theresearc...sleadinghealthcareexclusivecallcenter,issponsoring...ygenerationwithapositivecustomerserviceexperience....binarwillsupplementHowe,sJune2009whitepaper,"Custo...sseshowconsumerswillultimatelytransformhealthcared...
(Date:11/23/2009)...re/--CortivaInstituteTucsonwillhostanIntroductiont...theschool,s6390EastBroadwayBlvd.location,whichwill...icebasicmassagestrokes. ,, "Massagetherapyisagr...longwithit,"saidJoannMcMaster,presidentofCortivaIn...or,s2009-2010OccupationalOutlookHandbookstatesthat...
(Date:11/23/2009)...swire/--InasurveyofNewJerseyandPhiladelphiaregiona...2percentdonotbelieveanewhealthcarebillwouldlikelyr...esultsofthelatestsurveyconductedbytheAlloySilverst...ppedthelistat85percentasthebiggestnationalissue.Th...tocompaniesfromallpartsofNewJerseyandSoutheasternP...
(Date:11/23/2009)...nce Writings at Stevens Institute of Technology wi...t Wright, journalist and founder, Bloggingheads.tv...he Babbio Center for Technology Management, Room 1...he media., In his new book "The Evolution of God...ned for his popular works on evolutionary psycholo...
Breaking Medicine News(10 mins):Health News:RetireSafe Calls on Seniors to Grab their Bullhorns to Save Medicare from Rationed Care 2Health News:Tips to Improve Healthcare Customer Service Across All Generations 2Health News:Cortiva Institute To Host Workshop, Hands-On Opportunity for Prospective Students 2
...ncy-related blood pressure condition can pose seri...RIDAY, Oct. 17 (HealthDay News) -- Pregnant with h...minal pain and headaches until her symptoms worsen...is one of hundreds of women whose brush with preec...
...cademy of Ophthalmology hosts event October 24 ben... Sullivan headlines event, OKLAHOMA CITY, Oct. 17...e second annual "Eye Ball," benefiting the,Juvenil...Gary Story of Oklahoma City are the honorary chair...
...t. 17 American Well today announced that CEO,Roy ...product management;,and Michael Stollar, vice pres...s Blue Shield of Hawaii (HMSA), will provide a liv...t 10:00,a.m. PDT on October 23, 2008 at San Franci...
..., Calif., Oct. 17 Wyle is a key partner in,the wi...Center contract to,provide occupational health ser...year contract, valued at up to $24 million, is due...ealth physics,and respiratory protection., "We ar...
...sunderstand written screening tools, but ,talking,...17 (HealthDay News) -- Many patients misunderstand...answer before physical exams, a finding that calls...he American College of Surgeons, found that lower-...
...TON, Oct. 17 After a destructive,hurricane season... for,disasters, the American Public Health Associa...d ones are prepared for winter storms and any othe...make sure their emergency preparedness kits are st...
Other Medicine News:Health News:Research May Help Predict Preeclampsia 2Health News:Research May Help Predict Preeclampsia 3Health News:Research May Help Predict Preeclampsia 4Health News:Second Annual 'Eye Ball' Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology 2Health News:Second Annual 'Eye Ball' Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology 3Health News:American Well Systems CEO Roy Schoenberg to Present Live Public Demo of First Online Care Service at Health 2.0 Conference 2Health News:Wyle Key Part of Winning Team for Marshall Space Flight Center Occupational Health Services Contract 2Health News:Doctors Often Overestimate Patients' Health Literacy 2Health News:Check Your Emergency Preparedness Kits When You Set Your Clocks, Says American Public Health Association Campaign 2
(Date:11/23/2009)...re-FirstCall/--WoundManagementTechnologies,Inc.,(O...ialtymedicalproducts,announcedthatithasfileditQ320...gementbusinessupdatetoillustratethedevelopmentsdur...d33.5%to$102,926vs.Q32008salesof$77,084. , Sh...s.Q32008shareholderequityof$(321,257) , Total...
(Date:11/23/2009)...tCall/--CordBloodAmerica,Inc.(OTCBulletinBoard:CBA...y( http://www.cordblood-america.com )focusedonbrin...nsurancepolicy,tofamiliesnationwideandinternationa...thCEOandco-founderMatthewSchisslerisnowavailable. ...2875811 . ,, Intheinterview,Mr.Schisslerupdates...
(Date:11/23/2009)...-FirstCall/--RaptorPharmaceuticalCorp.("Raptor"ort...tationofclinicaltrialdataonNGX426,theCompany,soral...gonist,atthe12thInternationalConferenceontheMechan...-21inSanFrancisco.TheresultsofthestudyledbyMarkWal...nterforPainMedicineoftheUniversityofCaliforniaatSa...
Breaking Medicine Technology:Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 2Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 3Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 4Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 5Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health 28CDRH 29 4629 1Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health 28CDRH 29 4629 2Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health 28CDRH 29 4629 3CoAxia Inc Announces 2421 5M Series D Financing 4628 1CoAxia Inc Announces 2421 5M Series D Financing 4628 2CoAxia Inc Announces 2421 5M Series D Financing 4628 3Lilly Declares Third Quarter Dividend 49687 1
...e II study extension shows 68-73% of patients with... three years of treatment with oral FTY720,- New d...rain lesions - the injury caused by MS - thr...ating disease causing progressive disability, affe...g many young adults - FTY720 regulatory filings p...
... MEK inhibitor, RDEA119, demonstrates potential fo...nary Phase 1 results -, - Next generation MEK inh... half of 2008 -, SAN DIE...EA ) today announced that data was presented demon...okinetic profile of the Company,s,mitogen-activate...
Other Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors 2Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors 3Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors 4
...s a second generation nucleic acid amplification t...ive detection and differentiation of rRNA from CT ...ven technologies including target capture (TC), Tr...Kinetic Assay (DKA). This is the same family of te...
One-Step Gonorrhea Antigen Test
...on Information System) is an open architecture sys...tform designed to communicate and manage patient d...in various ways, as NAVIS can connect not only to ...halmic diagnostic equipment of other manufacturers...
...state technology, this laser emit true continuous-...d-state technology offers unsurpassed reliability,...lity, compact size allows easy transportation betw...tine laser maintenance. The EasyFit Adapter conver...
Medicine Products: